{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T22:10:16Z","timestamp":1719439816473},"reference-count":70,"publisher":"Becaris Publishing Limited","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:p>The first biosimilar infliximab, CT-P13 (infliximab-dyyb) has been used for the treatment of inflammatory diseases for 4\u00a0years. CT-P13 has highly similar efficacy and safety profiles with a lower price than the originator infliximab and has been approved in 81 countries. Despite approval for clinical use, some knowledge gaps still limit the widespread and pertinent use of biosimilar CT-P13. One of the most important factors for proper utilization of CT-P13 for the treatment of immune-mediated inflammatory diseases is confidence in CT-P13, which could be enhanced by scientific evidence supporting the biosimilarity of CT-P13. Overall, five randomized controlled studies have been performed. For the other extrapolated indications, many observational induction and switching studies also support the utility of CT-P13 in the treatment of inflammatory diseases. Here, we review profiles of CT-P13 including physicochemical properties, clinical efficacy and safety data in all indications and current status.<\/jats:p>","DOI":"10.2217\/cer-2017-0033","type":"journal-article","created":{"date-parts":[[2017,9,12]],"date-time":"2017-09-12T13:59:06Z","timestamp":1505224746000},"page":"693-712","source":"Crossref","is-referenced-by-count":3,"title":["Comparative effectiveness of the biosimilar CT-P13"],"prefix":"10.57264","volume":"6","author":[{"given":"Dae Hyun","family":"Yoo","sequence":"first","affiliation":[{"name":"Department of Rheumatology, College of Medicine, Hanyang University Hospital for Rheumatic Diseases, Hanyang University, 222\u20131 Wangsimni-ro Seongdong-gu, Seoul, 04763, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_2_3_2","unstructured":"GaBI Online . Generics and biosimilars Initiative. Biosimilar monoclonal antibody approved in Korea. www.gabionline.net\/Biosimilars\/News\/Biosimilar-monoclonal-antibody-approved-in-Korea"},{"key":"e_1_3_2_4_2","unstructured":"GaBI Online . Genereic and Biosimilars Initiatives. EMA approves first monoclonal antibody biosimilar. http:\/\/gabionline.net\/Biosimilars\/News\/EMA-approves-first-monoclonal-antibody-biosimilar"},{"key":"e_1_3_2_5_2","unstructured":"US FDA . FDA approves Inflectra a biosimilar to Remicade . www.fda.gov\/newsevents\/newsroom\/pressannouncements\/ucm494227.htm"},{"key":"e_1_3_2_6_2","unstructured":"WHO . Guidelines on evaluation of similar biotherapeutic products (SBPs) 19\u201323 Oct 2009 . www.who.int\/biologicals\/areas\/biological_therapeutics\/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf?ua=1"},{"key":"e_1_3_2_7_2","unstructured":"European Medicinal Agency . EMEA\/CHMP\/BMWP\/42832\/2005 Rev1. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues . www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2015\/01\/WC500180219.pdf"},{"key":"e_1_3_2_8_2","unstructured":"FDA USA . Biosimilars: additional questions and answers regarding implementation of the Biologics Price Competition and Innovation Act of 2009 Guidance for Industry . www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM273001.pdf"},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park W","year":"2013","unstructured":"Park W , Hrycaj P , Jeka S A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study . Ann. Rheum. Dis. 72 , 1605 \u2013 1612 ( 2013 ).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/annrheumdis-2012-203090","article-title":"A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study","volume":"72","author":"Yoo DH","year":"2013","unstructured":"Yoo DH , Hrycaj P , Miranda P A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study . Ann. Rheum. Dis. 72 , 1613 \u2013 1620 ( 2013 ).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_2_11_2","unstructured":"Pfizer Canada . Health Canada approves INFLECTRA \u00ae (biosimilar Infliximab) for three additional indications: Crohn\u2019s disease fistulating Crohn\u2019s disease and ulcerative colitis . www.pfizer.ca\/node\/7526"},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1007\/s12325-016-0431-5","article-title":"Awareness, knowledge, and perceptions of biosimilars among specialty physicians","volume":"33","author":"Cohen H","year":"2017","unstructured":"Cohen H , Beydoun D , Chien D Awareness, knowledge, and perceptions of biosimilars among specialty physicians . Adv. Ther. 33 , 2160 \u2013 2172 ( 2017 ).","journal-title":"Adv. Ther."},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40259-016-0202-5","article-title":"Rheumatologists\u2019 perceptions of biosimilar medicines prescription: findings from a French web-based survey","volume":"30","author":"Beck M","year":"2016","unstructured":"Beck M , Michel B , Rybarczyk-Vigouret MC Rheumatologists\u2019 perceptions of biosimilar medicines prescription: findings from a French web-based survey . BioDrugs 30 , 585 \u2013 592 ( 2016 ).","journal-title":"BioDrugs"},{"key":"e_1_3_2_14_2","first-page":"S9","article-title":"Likelihood of use and perception towards biosimilars in rheumatoid arthritis: a global survey of rheumatologists","volume":"34","author":"Narayanan S","year":"2016","unstructured":"Narayanan S , Nag S . Likelihood of use and perception towards biosimilars in rheumatoid arthritis: a global survey of rheumatologists . Clin. Exp. Rheumatol. 34 , S9 \u2013 S11 ( 2016 ).","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_3_2_15_2","unstructured":"Celltrion . CT-P13 (infliximab biosimilar) Briefing document for the arthritis advisory committee . www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/arthritisadvisorycommittee\/ucm484860.pdf"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.4161\/mabs.32221","article-title":"Physicochemical characterization of Remsima","volume":"6","author":"Jung SK","year":"2014","unstructured":"Jung SK , Lee KH , Jeon JW Physicochemical characterization of Remsima . MAbs 6 , 1163 \u2013 1177 ( 2014 ).","journal-title":"MAbs"},{"key":"e_1_3_2_17_2","first-page":"593","article-title":"Comparable immune function inhibition by the infliximab biosimilar CT-P13: implications for treatment of inflammatory bowel disease","volume":"11","author":"Lim KJ","year":"2017","unstructured":"Lim KJ , Lee SJ , Kim S Comparable immune function inhibition by the infliximab biosimilar CT-P13: implications for treatment of inflammatory bowel disease . J. Crohns Colitis 11 , 593 \u2013 602 ( 2017 ).","journal-title":"J. Crohns Colitis"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.cgh.2016.05.023","article-title":"Biosimilars in inflammatory bowel disease: facts and fears of extrapolation","volume":"14","author":"Ben-Horin S","year":"2016","unstructured":"Ben-Horin S , Vande Casteele N , Schreiber S , Lakatos PL . Biosimilars in inflammatory bowel disease: facts and fears of extrapolation . Clin. Gastroenterol. Hepatol. 14 , 1685 \u2013 1696 ( 2016 ).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3109\/14397595.2015.1022297","article-title":"Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis","volume":"25","author":"Takeuchi T","year":"2015","unstructured":"Takeuchi T , Yamanaka H , Tanaka Y Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis . Mod. Rheumatol. 25 , 817 \u2013 824 ( 2015 ).","journal-title":"Mod. Rheumatol."},{"issue":"1","key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1586\/1744666X.2015.1090311","article-title":"Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study","volume":"11","author":"Park W","year":"2015","unstructured":"Park W , Lee SJ , Yun J , Yoo DH . Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study . Expert Rev. Clin. Immunol. 11 ( Suppl. 1 ), S25 \u2013 S31 ( 2015 ).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/S0016-5085(17)30571-1","article-title":"Phase III randomized double-blinded, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab (INX) in patients with active Crohn\u2019s disease: early efficacy and safety results","volume":"152","author":"Kim YH","year":"2017","unstructured":"Kim YH , Ye BD , Pesegova M Phase III randomized double-blinded, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab (INX) in patients with active Crohn\u2019s disease: early efficacy and safety results . Gastroenterology 152 , S65 ( 2017 ).","journal-title":"Gastroenterology"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13075-016-0981-6","article-title":"A Phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study","volume":"18","author":"Yoo DH","year":"2016","unstructured":"Yoo DH , Racewicz A , Brzezicki J A Phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study . Arthritis Res. Ther. 18 , 82 ( 2016 ).","journal-title":"Arthritis Res. Ther."},{"issue":"6","key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00296-017-3663-z","article-title":"Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab","volume":"37","author":"Sung YK","year":"2017","unstructured":"Sung YK , Cho SK , Kim D Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab . Rheumatol. Int. 37 ( 6 ), 1007 \u2013 1014 ( 2017 ).","journal-title":"Rheumatol. Int."},{"key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13075-016-0930-4","article-title":"Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study","volume":"18","author":"Park W","year":"2016","unstructured":"Park W , Yoo DH , Jaworski J Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study . Arthritis Res. Ther. 18 , 25 ( 2016 ).","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1586\/17474124.2015.1091308","article-title":"Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study","volume":"9","author":"Jahnsen J","year":"2015","unstructured":"Jahnsen J , Detlie TE , Vatn S , Ricanek P . Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study . Expert Rev. Gastroenterol. Hepatol. 9 ( Suppl. 1 ), 45 \u2013 52 ( 2015 ).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1517\/14712598.2015.1064893","article-title":"Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn\u2019s disease and ulcerative colitis \u2013 experiences from a single center","volume":"15","author":"Farkas K","year":"2015","unstructured":"Farkas K , Rutka M , Balint A Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn\u2019s disease and ulcerative colitis \u2013 experiences from a single center . Expert Opin. Biol. Ther. 15 , 1257 \u2013 1262 ( 2015 ).","journal-title":"Expert Opin. Biol. Ther."},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/ecco-jcc\/jjv220","article-title":"Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort","volume":"10","author":"Gecse KB","year":"2016","unstructured":"Gecse KB , Lovasz BD , Farkas K Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: a prospective, multicentre, nationwide cohort . J. Crohns Colitis 10 , 133 \u2013 140 ( 2016 ).","journal-title":"J. Crohns Colitis"},{"key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3109\/00365521.2016.1149883","article-title":"Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn\u2019s disease and ulcerative colitis","volume":"51","author":"Keil R","year":"2016","unstructured":"Keil R , Wasserbauer M , Zadorova Z Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn\u2019s disease and ulcerative colitis . Scand. J. Gastroenterol. 51 , 1062 \u2013 1068 ( 2016 ).","journal-title":"Scand. J. Gastroenterol."},{"key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/ecco-jcc\/jjw085","article-title":"Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis","volume":"10","author":"Farkas K","year":"2016","unstructured":"Farkas K , Rutka M , Golovics PA Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis . J. Crohns Colitis 10 , 1273 \u2013 1278 ( 2016 ).","journal-title":"J. Crohns Colitis"},{"key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"514","DOI":"10.14735\/amgh2016514","article-title":"Biosimilar infliximab in anti-TNF-naive IBD patients \u2013 1-year clinical follow-up","volume":"70","author":"Kolar M","year":"2016","unstructured":"Kolar M , Duricova D , Bortlik M Biosimilar infliximab in anti-TNF-naive IBD patients \u2013 1-year clinical follow-up . Gastroent. Hepatol. 70 , 514 \u2013 522 ( 2016 ).","journal-title":"Gastroent. Hepatol."},{"key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/ecco-jcc\/jjw087","article-title":"Clinical outcomes following a switch from Remicade(R) to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study","volume":"10","author":"Smits LJ","year":"2016","unstructured":"Smits LJ , Derikx LA , de Jong DJ Clinical outcomes following a switch from Remicade(R) to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study . J. Crohns Colitis 10 , 1287 \u2013 1293 ( 2016 ).","journal-title":"J. Crohns Colitis"},{"issue":"3","key":"e_1_3_2_32_2","first-page":"297","article-title":"Switching from Remicade(R) to Remsima(R) is well tolerated and feasible: a prospective, open-label study","volume":"11","author":"Buer LC","year":"2016","unstructured":"Buer LC , Moum BA , Cvancarova M , Warren DJ , Medhus AW , Hoivik ML . Switching from Remicade(R) to Remsima(R) is well tolerated and feasible: a prospective, open-label study . J. Crohns Colitis 11 ( 3 ), 297 \u2013 304 ( 2016 ).","journal-title":"J. Crohns Colitis"},{"key":"e_1_3_2_33_2","first-page":"690","article-title":"Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme","volume":"11","author":"Razanskaite V","year":"2017","unstructured":"Razanskaite V , Bettey M , Downey L Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme . J. Crohns Colitis 11 , 690 \u2013 696 ( 2017 ).","journal-title":"J. Crohns Colitis"},{"key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/MIB.0000000000000995","article-title":"The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar","volume":"23","author":"Fiorino G","year":"2017","unstructured":"Fiorino G , Manetti N , Armuzzi A The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar . Inflamm. Bowel Dis. 23 , 233 \u2013 243 ( 2017 ).","journal-title":"Inflamm. Bowel Dis."},{"key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000449088","article-title":"Experience with biosimilar infliximab (Remsima(R)) in Norway","volume":"35","author":"Jahnsen J","year":"2017","unstructured":"Jahnsen J , Kaasen Jorgensen K . Experience with biosimilar infliximab (Remsima(R)) in Norway . Dig. Dis. 35 , 83 \u2013 90 ( 2017 ).","journal-title":"Dig. Dis."},{"key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000453343","article-title":"Infliximab biosimilar (Remsima) in therapy of inflammatory bowel diseases patients: experience from one tertiary inflammatory bowel diseases centre","volume":"35","author":"Kolar M","year":"2017","unstructured":"Kolar M , Duricova D , Bortlik M Infliximab biosimilar (Remsima) in therapy of inflammatory bowel diseases patients: experience from one tertiary inflammatory bowel diseases centre . Dig. Dis. 35 , 91 \u2013 100 ( 2017 ).","journal-title":"Dig. Dis."},{"key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s10620-017-4511-4","article-title":"Effectiveness and safety of CT-P13 (biosimilar infliximab) in patients with inflammatory bowel disease in real life at 6 months","volume":"62","author":"Arguelles-Arias F","year":"2017","unstructured":"Arguelles-Arias F , Guerra Veloz MF , Perea Amarillo R Effectiveness and safety of CT-P13 (biosimilar infliximab) in patients with inflammatory bowel disease in real life at 6 months . Dig. Dis. Sci. 62 , 1305 \u2013 1312 ( 2017 ).","journal-title":"Dig. Dis. Sci."},{"key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/jgh.12997","article-title":"Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study","volume":"30","author":"Jung YS","year":"2015","unstructured":"Jung YS , Park DI , Kim YH Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study . J. Gastroenterol. Hepatol. 30 , 1705 \u2013 1712 ( 2015 ).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1586\/17474124.2015.1091309","article-title":"Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea","volume":"9","author":"Park SH","year":"2015","unstructured":"Park SH , Kim YH , Lee JH Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea . Expert Rev. Gastroenterol. Hepatol. 9 ( Suppl. 1 ), 35 \u2013 44 ( 2015 ).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"S333","DOI":"10.1093\/ecco-jcc\/jjx002.624","article-title":"Effectiveness and safety in Crohn\u2019s disease patients who were treated with CT-P13","volume":"11","author":"Choe YH","year":"2017","unstructured":"Choe YH , Lee SH , Park DI Effectiveness and safety in Crohn\u2019s disease patients who were treated with CT-P13 . J. Crohns Colitis 11 , S333 ( P500 ) ( 2017 ).","journal-title":"J. Crohns Colitis"},{"key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s10620-014-3392-z","article-title":"Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series","volume":"60","author":"Kang YS","year":"2015","unstructured":"Kang YS , Moon HH , Lee SE , Lim YJ , Kang HW . Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series . Dig. Dis. Sci. 60 , 951 \u2013 956 ( 2015 ).","journal-title":"Dig. Dis. Sci."},{"issue":"8","key":"e_1_3_2_42_2","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/apt.13990","article-title":"Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases","volume":"45","author":"Komaki Y","year":"2017","unstructured":"Komaki Y , Yamada A , Komaki F , Micic D , Ido A , Sakuraba A . Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases . Aliment. Pharmacol. Ther. 45 ( 8 ), 1043 \u2013 1057 ( 2017 ).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"e_1_3_2_43_2","first-page":"P370","article-title":"First observations of the use of biosimilar infliximab for treatment of ulcerative colitis and Crohn\u2019s disease in paediatric population","volume":"3","author":"Jarzebicka D","year":"2015","unstructured":"Jarzebicka D , Sieczkowska J , Dadalski M , Kierkus J . First observations of the use of biosimilar infliximab for treatment of ulcerative colitis and Crohn\u2019s disease in paediatric population . United Eur. Gastroenterol. J. 3 , P370 ( 2015 ).","journal-title":"United Eur. Gastroenterol. J."},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1177\/1756283X16650155","article-title":"Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases","volume":"9","author":"Sieczkowska J","year":"2016","unstructured":"Sieczkowska J , Jarzebicka D , Meglicka M , Oracz G , Kierkus J . Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases . Therap. Adv. Gastroenterol. 9 , 729 \u2013 735 ( 2016 ).","journal-title":"Therap. Adv. Gastroenterol."},{"key":"e_1_3_2_45_2","doi-asserted-by":"crossref","first-page":"A259","DOI":"10.1136\/gutjnl-2016-312388.487","article-title":"Comparison of efficacy and safety of biosimilar infliximab to originator infliximab in children with inflammatory bowel disease","volume":"65","author":"Muhammed R","year":"2016","unstructured":"Muhammed R , Wong T , Haller W , Protheroe S , Whyte L , Bremner R . Comparison of efficacy and safety of biosimilar infliximab to originator infliximab in children with inflammatory bowel disease . Gut 65 , A259 \u2013 A260 ( 2016 ).","journal-title":"Gut"},{"issue":"3","key":"e_1_3_2_46_2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/MPG.0000000000001643","article-title":"Induction therapy with biosimilar infliximab in children with Crohn\u2019s disease","volume":"65","author":"Sieczkowska-Golub J","year":"2017","unstructured":"Sieczkowska-Golub J , Meglicka M , Plocek A Induction therapy with biosimilar infliximab in children with Crohn\u2019s disease . J. Pediatr. Gastroenterol. Nutr. 65 ( 3 ), 491 \u2013 493 ( 2017 ).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"e_1_3_2_47_2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/jdv.12876","article-title":"First experience with therapy of severe forms of psoriasis with biosimilar infliximab","volume":"30","author":"Tichy M","year":"2016","unstructured":"Tichy M , Kopova R , Sternbersky J . First experience with therapy of severe forms of psoriasis with biosimilar infliximab . J. Eur. Acad. Dermatol. Venereol. 30 , 491 \u2013 493 ( 2016 ).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"e_1_3_2_48_2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.04.068","article-title":"The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis","volume":"75","author":"Dapavo P","year":"2016","unstructured":"Dapavo P , Vujic I , Fierro MT , Quaglino P , Sanlorenzo M . The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis . J. Am. Acad. Dermatol. 75 , 736 \u2013 739 ( 2016 ).","journal-title":"J. Am. Acad. Dermatol."},{"key":"e_1_3_2_49_2","doi-asserted-by":"crossref","DOI":"10.1111\/bjd.15659","article-title":"Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis. Data from the Psobiosimilars registry","author":"Gisondi P","year":"2017","unstructured":"Gisondi P , Bianchi L , Conti A Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis. Data from the Psobiosimilars registry . Br. J. Dermatol. doi:10.1111\/bjd.15659 ( Epub ahead of print ) ( 2017 ).","journal-title":"Br. J. Dermatol."},{"key":"e_1_3_2_50_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/annrheumdis-2015-208786","article-title":"Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study","volume":"76","author":"Yoo DH","year":"2017","unstructured":"Yoo DH , Prodanovic N , Jaworski J Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study . Ann. Rheum. Dis. 76 , 355 \u2013 363 ( 2017 ).","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"e_1_3_2_51_2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/14397595.2016.1206244","article-title":"Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab","volume":"27","author":"Tanaka Y","year":"2017","unstructured":"Tanaka Y , Yamanaka H , Takeuchi T Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab . Mod. Rheumatol. 27 ( 2 ), 237 \u2013 245 ( 2017 ).","journal-title":"Mod. Rheumatol."},{"key":"e_1_3_2_52_2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/annrheumdis-2015-208783","article-title":"Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study","volume":"76","author":"Park W","year":"2017","unstructured":"Park W , Yoo DH , Miranda P Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study . Ann. Rheum. Dis. 76 , 346 \u2013 354 ( 2017 ).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"e_1_3_2_53_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12026-016-8843-5","article-title":"Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study","volume":"65","author":"Benucci M","year":"2017","unstructured":"Benucci M , Gobbi FL , Bandinelli F Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study . Immunol. Res. 65 ( 1 ), 419 \u2013 422 ( 2017 ).","journal-title":"Immunol. Res."},{"key":"e_1_3_2_54_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1093\/ecco-jcc\/jjv233","article-title":"Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations","volume":"10","author":"Sieczkowska J","year":"2016","unstructured":"Sieczkowska J , Jarzebicka D , Banaszkiewicz A Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary observations . J. Crohns Colitis 10 , 127 \u2013 132 ( 2016 ).","journal-title":"J. Crohns Colitis"},{"key":"e_1_3_2_55_2","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1517\/14712598.2015.1103733","article-title":"Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data","volume":"15","author":"Nikiphorou E","year":"2015","unstructured":"Nikiphorou E , Kautiainen H , Hannonen P Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data . Expert Opin. Biol. Ther. 15 , 1677 \u2013 1683 ( 2015 ).","journal-title":"Expert Opin. Biol. Ther."},{"key":"e_1_3_2_56_2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40259-017-0219-4","article-title":"Evaluation of the cross-reactivity of antidrug antibodies to CT-P13 and infliximab reference product (Remicade): an analysis using immunoassays tagged with both agents","volume":"31","author":"Reinisch W","year":"2017","unstructured":"Reinisch W , Jahnsen J , Schreiber S Evaluation of the cross-reactivity of antidrug antibodies to CT-P13 and infliximab reference product (Remicade): an analysis using immunoassays tagged with both agents . BioDrugs 31 , 223 \u2013 237 ( 2017 ).","journal-title":"BioDrugs"},{"key":"e_1_3_2_57_2","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"Jorgensen KK","year":"2017","unstructured":"Jorgensen KK , Olsen IC , Goll GL Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial . Lancet 389 , 2304 \u2013 2316 ( 2017 ).","journal-title":"Lancet"},{"key":"e_1_3_2_58_2","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","article-title":"A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry","volume":"76","author":"Glintborg B","year":"2017","unstructured":"Glintborg B , Sorensen IJ , Loft AG A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry . Ann. Rheum. Dis. 76 , 1426 \u2013 1431 ( 2017 ).","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"e_1_3_2_59_2","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1586\/1744666X.2015.1090312","article-title":"Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13)","volume":"11","author":"Kim JS","year":"2015","unstructured":"Kim JS , Kim SH , Kwon B , Hong S . Comparison of immunogenicity test methods used in clinical studies of infliximab and its biosimilar (CT-P13) . Expert Rev. Clin. Immunol 11 ( Suppl. 1 ), S33 \u2013 S41 ( 2015 ).","journal-title":"Expert Rev. Clin. Immunol"},{"key":"e_1_3_2_60_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40259-016-0174-5","article-title":"Assessing the immunogenicity of biopharmaceuticals","volume":"30","author":"Pineda C","year":"2016","unstructured":"Pineda C , Castaneda Hernandez G , Jacobs IA , Alvarez DF , Carini C . Assessing the immunogenicity of biopharmaceuticals . BioDrugs 30 , 195 \u2013 206 ( 2016 ).","journal-title":"BioDrugs"},{"issue":"10","key":"e_1_3_2_61_2","article-title":"Non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis \u2013 impact on s-infliximab and antidrug-antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry","volume":"68","author":"Glintborg B","year":"2016","unstructured":"Glintborg B , Kringelbach TM , H\u00f8gdall E Non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis \u2013 impact on s-infliximab and antidrug-antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry . Arthritis Rheumatol. 68 ( Suppl. 10 ), Abstr. 1997 ( 2016 ).","journal-title":"Arthritis Rheumatol."},{"key":"e_1_3_2_62_2","unstructured":"GaBI Online . Biosimilars approved in Europe . www.gabionline.net\/Biosimilars\/General\/Biosimilars-approved-in-Europe"},{"key":"e_1_3_2_63_2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.biologicals.2016.03.006","article-title":"Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health","volume":"44","author":"Braun J","year":"2016","unstructured":"Braun J , Kudrin A . Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health . Biologicals 44 , 257 \u2013 266 ( 2016 ).","journal-title":"Biologicals"},{"key":"e_1_3_2_64_2","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/annrheumdis-2015-208684","article-title":"Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars","volume":"75","author":"Ruiz-Arguello MB","year":"2016","unstructured":"Ruiz-Arguello MB , Maguregui A , Ruiz Del Agua A Antibodies to infliximab in Remicade-treated rheumatic patients show identical reactivity towards biosimilars . Ann. Rheum. Dis. 75 , 1693 \u2013 1696 ( 2016 ).","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_3_2_65_2","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/MIB.0000000000000709","article-title":"Harmonization of infliximab and anti-infliximab assays facilitates the comparison between originators and biosimilars in clinical samples","volume":"22","author":"Gils A","year":"2016","unstructured":"Gils A , Van Stappen T , Dreesen E , Storme R , Vermeire S , Declerck PJ . Harmonization of infliximab and anti-infliximab assays facilitates the comparison between originators and biosimilars in clinical samples . Inflamm. Bowel Dis. 22 , 969 \u2013 975 ( 2016 ).","journal-title":"Inflamm. Bowel Dis."},{"key":"e_1_3_2_66_2","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/gutjnl-2015-309290","article-title":"Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima","volume":"65","author":"Ben-Horin S","year":"2016","unstructured":"Ben-Horin S , Yavzori M , Benhar I Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima . Gut 65 , 1132 \u2013 1138 ( 2016 ).","journal-title":"Gut"},{"issue":"1","key":"e_1_3_2_67_2","first-page":"S15","article-title":"Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product","volume":"11","author":"Yoo DH","year":"2015","unstructured":"Yoo DH , Oh C , Hong S , Park W . Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product . Expert Rev. Clin. Immunol. 11 ( Suppl. 1 ), S15 \u2013 S24 ( 2015 ).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"e_1_3_2_68_2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/14740338.2017.1323330","article-title":"Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort","volume":"16","author":"Balint A","year":"2017","unstructured":"Balint A , Rutka M , Vegh Z Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort . Expert Opin. Drug Saf. 16 , 885 \u2013 890 ( 2017 ).","journal-title":"Expert Opin. Drug Saf."},{"key":"e_1_3_2_69_2","unstructured":"European Medicines Agency : Assessment report; Remsima . www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/002576\/WC500151486.pdf"},{"key":"e_1_3_2_70_2","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/art.39546","article-title":"Brief report: utilization of the first biosimilar infliximab since its approval in South Korea","volume":"68","author":"Kim SC","year":"2016","unstructured":"Kim SC , Choi NK , Lee J Brief report: utilization of the first biosimilar infliximab since its approval in South Korea . Arthritis Rheumatol. 68 , 1076 \u2013 1079 ( 2016 ).","journal-title":"Arthritis Rheumatol."},{"key":"e_1_3_2_71_2","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10067-017-3584-y","article-title":"Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry","volume":"36","author":"Park DJ","year":"2017","unstructured":"Park DJ , Choi SJ , Shin K Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry . Clin. Rheumatol. 36 , 1013 \u2013 1022 ( 2017 ).","journal-title":"Clin. Rheumatol."},{"key":"e_1_3_2_72_2","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1093\/ecco-jcc\/jjx002.706","article-title":"The pharmacoeconomic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016","volume":"11","author":"Han S","year":"2017","unstructured":"Han S , Kim S , Kim J The pharmacoeconomic impact of biosimilar infliximab (CT-P13) in Europe from January 2015 to June 2016 . J. Crohns Colitis 11 , S377 ( 2017 ).","journal-title":"J. Crohns Colitis"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer-2017-0033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T21:56:33Z","timestamp":1719438993000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer-2017-0033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":70,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.2217\/cer-2017-0033"],"URL":"https:\/\/doi.org\/10.2217\/cer-2017-0033","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}